Humacyte, Inc. (NASDAQ: HUMA) is a Healthcare company (Biotechnology) with a market capitalization of $139M. The Maz Rating grades it against the other companies in its sector.
Humacyte, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $0.50, Humacyte, Inc. trades at 58.7x sales and 7.8x book value. Over the last twelve months it generated about $2M of revenue and a net loss of $126M. It runs a gross margin of -549.7%, an operating margin of -4602.9% and a net margin of -3955.1%. It shows return on equity of -591.7%, return on invested capital of -109.4% and a free cash flow yield of -63.1%. On the balance sheet: a debt-to-equity ratio of 3.65 and a current ratio of 3.34. Over the past 52 weeks the share price ranged from $0.34 to $1.53, with a beta of 2.68.
Humacyte, Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 9 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.